Fluticasone propionate HFA inhalation — Point32Health
maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients aged ≥ 4 years
Preferred products
- Arnuity Ellipta
- Qvar RediHaler
Initial criteria
- Patient age ≥ 7 years
- Patient has had a trial of at least two (2) Step-1 medications (Arnuity Ellipta AND Qvar RediHaler) as evidenced by physician’s documented use, excluding the use of samples OR Patient has contraindication or intolerance to two (2) Step-1 medications (i.e., inability to use the preferred inhalation devices)
Approval duration
12 months